ENTX
Entera Bio Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$3.00
+1.69%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−35.7x
Market Cap
$519.43M
MomentumView details →
1D Return
+1.69%
YTD Return
+56.64%
RSI (14)
55.3
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−35.7x
Market Cap
$519.43M
RSI (14)
55.3
MomentumView details →
1D Return
+1.69%
YTD Return
+56.64%
SummaryUpdated Jun 1, 2026
Entera Bio Ltd. (NASDAQ:ENTX) is a clinical-stage biopharmaceutical company founded in 2009 and headquartered in Jerusalem, Israel. The company went public in June 2018 and specializes in developing oral delivery technologies for large molecule therapeutics, particularly focusing on treatments for bone-related disorders and other unmet medical needs. Entera Bio has established itself as a pioneer in the challenging field of oral delivery of large molecules, which traditionally require injection due to their poor absorption when taken orally.
Similar companies
Latest newsMore news →
Entera Bio announced plans to start a Phase 3 registrational trial for its oral osteoporosis drug EB613 after reaching agreement with the U.S. FDA on a 12-month placebo-controlled study design.22d agoEntera Bio Ltd. priced an oversubscribed $275 million private placement led by existing investor BVF Partners L.P.40d ago